Media

VIENNA, Va.–(BUSINESS WIRE)–

Over the past three months, patient screening by participating hospitals and patient enrollment have steadily increased. In fact, we are even now seeing patient enrollment at centers that had not enrolled any patients under the prior Clinical Research Organization (CRO), inVentiv Health. CEL-SCI expects to see a further increase in the number of patients enrolled in the study at an accelerating pace as (i) the current centers finalize all logistical issues and (ii) an additional 50-60 centers are added throughout the world. Full enrollment of the planned 880 patients is expected by the end of 2015.

Per the study’s protocol design, four out of every seven patients enrolled are randomized to treatment with Multikine followed by the current standard of care (SOC) treatment, which is surgery plus radiotherapy or surgery plus concurrent radiochemotherapy. The remaining three patients receive SOC only – the control-treatment comparator group. In accordance with the protocol design, of the approximate 146 patients enrolled, an estimated 84 have already been dosed with Multikine.

The study’s Independent Data Monitoring Committee (IDMC), a committee of prominent physicians and scientists from around the world, already has completed two interim reviews of the unblinded trial data. Following each review, the IDMC concluded that the patient data raised no safety concerns and recommended that the Phase III study continue unmodified.

“We are very pleased with the acceleration of our study and based on what we are told by our current CROs Ergomed and Aptiv Solutions, we believe that both patient accrual and the study will continue to advance at a faster pace in the coming months,” stated CEL-SCI Chief Executive Officer Geert Kersten.

Most of the patient enrollment is under the control of Ergomed who has signed three co-development agreements for Multikine with CEL-SCI. The agreement concerning head and neck cancer calls for an investment by Ergomed of up to $10 million into the ongoing Phase III clinical trial. Ergomed will be repaid from future sales of Multikine, following regulatory approval.

Pompano Beach, Feb. 27, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare’s line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company’s broader strategy as it continues to build the premier global brand in clinically proven personal care products.

DS Laboratories, the Company’s flagship brand is now sold in over 15 countries, helping address a global and underserved problem of hair loss. The Company’s first retail store in Miami will continue to increase brand awareness while adding to revenues and gross margins.

“Customers worldwide who have tried our products have a passion for them because they work. We believe our products, in particular our hair loss formulations, are the most effective on the market. With the opening of our first DS Laboratories retail store, we create an opportunity to increase our direct connection with consumers, leverage our marketing and advertising campaigns, and drive greater demand to the thousands of stores and salons that already carry our products,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

WILMINGTON, Mass., Feb. 27, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detection system has successfully completed and passed testing requirements of the Qualification Testing and Evaluation (QT&E) portion of the Transportation Security Administration’s (TSA) Explosive Trace Detection (ETD) qualification test at the Transportation Systems Integration Facility (TSIF).

TSA’s state-of-the-art TSIF, located at Ronald Reagan Washington National Airport, is where new screening technologies are tested before they are deployed to airports around the country. The facility provides an operational airport environment where TSA evaluates the technology by its concepts of operation, measures of performance, and measures of effectiveness.

In July 2013, the QS-B220 successfully completed the first step of QT&E, called Independent Testing and Evaluation (IT&E). QS-B220 has since passed the second step of QT&E at the TSIF, thereby fulfilling another important step towards qualifying the QS-B220 by the Transportation Security Administration and for use in major airports all across the US.

“Evaluation of our QS-B220 was a very important achievement that demonstrates the benefits of our ETD technology in action. The QS-B220 provides superior detection capabilities, a non-radioactive source, and operational and cost efficiencies that can deliver benefits at airport security checkpoints each year. The combination of enhanced performance and operational capabilities of the QS-B220 truly define the new standard of trace detection,” stated Glenn D. Bolduc, Implant Sciences’ President and CEO.

“Successfully completing QT&E brings us another step closer to completing TSA’s Qualified Product List process, and we are confident that the QS-B220 will meet the remaining stringent testing requirements,” added Dr. Darryl Jones, Vice President of Sales and Marketing at Implant Sciences.

HAIFA, Israel, Feb. 20, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration requesting the Company to be granted Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells in the treatment of severe preeclampsia.

Orphan Drug Designation may qualify a company for several benefits under the Orphan Drug Act of 1983 (ODA), as amended. These benefits may include a 7-year period of orphan drug exclusivity upon product approval, a tax credit for certain clinical testing expenses for the orphan drug, written guidance on the non-clinical and clinical studies needed to obtain marketing approval of an orphan drug, and orphan drug grants.

“Having just recently established our Preeclampsia Steering Committee comprised of key medical opinion leaders, this Orphan Drug application submission is an important step in advancing our preeclampsia development program,” stated Pluristem Chairman and CEO Zami Aberman. “The tremendous unmet medical need makes this indication one of our top priorities. We look forward to advancing into human trials and we are hopeful that the very strong preclinical data for PLX cells will translate into similar results at the clinical level.”

Pluristem has successfully received Orphan Drug Designation from the FDA for its PLX cells in two other indications: the treatment of aplastic anemia; and the treatment of Buerger’s disease.

About Preeclampsia

Preeclampsia is one of the most common medical complications of pregnancy, and one of the leading known causes of premature births, stillbirths and early neonatal and maternal deaths. If left untreated it can progress to eclampsia, the life-threatening occurrence of seizures during pregnancy. The only definitive treatment for preeclampsia is abortion or delivery. The disease occurs after the 20th week of pregnancy, and is characterized by high blood pressure and significant amounts of protein in the urine or end-organ dysfunction. According to the World Health Organization, preeclampsia occurs in approximately 6%–8% of pregnancies worldwide. It is estimated that preeclampsia costs the global health care system $3 billion annually.

WILMINGTON, Mass., Feb. 20, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the Company’s President & CEO, Glenn Bolduc has been invited by the United States Department of Commerce’s International Trade Administration Advocacy Center to participate in a roundtable discussion at the White House on Friday February 21, 2014. The purpose of the meeting is to discuss how the Advocacy Center can best assist American companies in their efforts to export. Mr. Bolduc has been asked to make a brief presentation on Implant Sciences and how its export initiatives have been supported by the Advocacy Center.

“We are honored to be invited to make this presentation at the White House. Implant Sciences has benefitted from the U.S. Department of Commerce’s Advocacy Center. We can directly attribute millions of dollars in sales that have resulted from Advocacy Center introductions and support,” Bolduc stated. “As the only U.S.-owned and operated manufacturer of explosives trace detection equipment to have product approval from the TSA, we are proud to contribute to America’s exports and to create high-tech jobs in the U.S.”

Implant Sciences has an expanding global presence and has sold over 2,000 explosives trace detectors in more than 50 countries. The U.S. Department of Commerce’s Advocacy Center has helped support Implant Sciences’ sales efforts in many locations and was critical in completing the Company’s $6 million contract with the Indian government in 2012. With 75 employees, Implant Sciences’ ETDs are 100% manufactured in the USA.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company’s QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. For further details on the Company and its products, please visit the Company’s website at http://www.implantsciences.com.

HAIFA, Israel, Feb. 18, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem’s key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem’s third patent issued in Australia and its 28th patent issued worldwide.

Pluristem’s PLacental eXpanded (PLX) PAD cells have been approved for a Phase I study in Australia for the treatment of Pulmonary Arterial Hypertension (PAH). United Therapeutics will be conducting the trial under a licensing agreement with Pluristem.

“Australia represents a significant and attractive healthcare market for the largest biotech and pharmaceutical companies. Because this patent covers manufacturing methods for producing commercial quantities of cells, it is very valuable intellectual property for Pluristem and the patent can be a key asset for potential partnership and licensing opportunities for us in Australia,” stated Zami Aberman, Chairman and CEO of Pluristem.

Pluristem’s Australian patent announced on January 8, 2014 covers the use of adherent placental cells for the treatment of ischemia, which is a restriction of blood supply to tissues, and for treatments of conditions requiring connective tissue repair or regeneration.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Pompano Beach, Feb. 10, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions.

“This agreement with a leader in the global healthcare market is a clear indication of the strength of our innovation. DS Healthcare has built a reputation of excellence for our products that has led to this agreement. This is an exciting project that we believe will reach new milestones for us,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

WILMINGTON, Mass., Feb. 13, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences’ fiscal year 2014 for deployment in Latin America.

Hector Giraldo, Managing Director, Americas for Implant Sciences commented, “We have been supplying trace detection equipment to Latin America since 2008. Our ETDs are widely used across the region and our reputation for performance was a key factor in winning this contract. The customer also clearly favored our systems’ non-radioactive source and non-contact particle sampling technology.”

“Latin America is a market which holds great growth potential for us. Hector has done a great job of expanding our presence in the region,” added Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones. “Our superior technology, regulatory approvals, and excellent sales and service combine to expand our global footprint.”

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

WILMINGTON, Mass., Feb. 6, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold 20 QS-H150 explosives trace detectors (ETD) to a construction company in Asia. The handheld QS-H150s will be used to protect construction sites, including perimeter security, for the construction company which is building secure infrastructure-grade facilities.

“We were pleased to win this sizable contract in a competitive situation against other larger vendors. Through deployments in a wide range of applications around the world, the QS-H150 has proven it performs well in outdoor environments and its detection capabilities are not hampered by particles like sand or construction dust,” commented Implant Sciences’ VP of Sales and Marketing, Darryl Jones. “The portability, ease of use, and reliability of the QS-H150 were fundamental advantages which led to the customer’s purchase decision.”

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

BOTHELL, WA–(Marketwired – Feb 6, 2014) – Borneo Resource Investments Ltd. (OTCQB: BRNE) (the “Company” or “Borneo”), a mining company that mines gold and develops producing gold mines as well as coal mining properties in Indonesia, today announced it is actively mining its Ratatotok South gold property and has successfully completed its first full scale production test run there. Ratatotok South was acquired by Borneo in December 2013, through its subsidiary PT Puncak Kalabat. This is the Company’s second producing gold mine. Borneo commenced mining gold at its first producing mine, Talawaan, in June of 2013.

Borneo CEO Nils Ollquist commented, “Based on the results of our production test run, we expect to complete two processing runs per month on a regular basis at Ratatotok South. We are very encouraged by the productivity at the mine. The infrastructure and equipment that came with the property when we purchased it played a key role in accelerating our time to production. A primary driving operational goal for us is to begin producing as soon as is feasible on each of our newly acquired gold mines. Clearly, we’ve demonstrated our ability to achieve that.”

The 8.5 hectare Ratatotok South property is located in the middle of a well-established gold reef structure. It is adjacent to Ratatotok Southeast, which Borneo acquired, also through its subsidiary PT Puncak Kalabat, in January 2014 and Ratatotok, which was acquired in March of 2013.

About Borneo Resource Investments Ltd.
Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mines as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include three gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.